Gate™ Tricuspid Valved Stent

NCSI has shown that it is feasible to deliver and deploy the Atrioventricular Valved Stent (AVS) using the GATE System as a tricuspid valve replacement in animal model in the modes as shown:

The AVS device sizes offered are:
30/40 mm; 33/44 mm & 36/48 mm

Indications For Use:

The Need for a Mitral and Tricuspid Valved Stent

Mitral Regurgitation Patient Population in USA Currently Treated % Treated
Moderate to Severe 2,3000,000 48,000 2.1%
Severe 220,000 48,000 22%
Tricuspid regurgitation: 1,600,000 < 8,000
Moderate to Severe < 8,000 < 0.5%

**Stuge O and Liddicoat J: Emerging Opportunities for Cardiac Surgeons within Structural Heart Disease.
J Thorac and Cardiovasc Surgery: 132:1258-1261 (2006)